ALT - CIK 0001326190
The table below shows Altimmune, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$67.53M | -$79.85M | -$75.81M | -$62.59M | -$78.24M | -$34.31M |
| Capital expenditure | $11.00K | - | $47.00K | $126.00K | $12.12M | $203.96K |
| Investing cash flow | -$132.47M | -$28.39M | $13.73M | -$73.40M | $87.52M | -$72.23M |
| Dividends paid | - | - | - | - | - |
Altimmune, Inc. reported operating cash flow of -$67.53M for fiscal year 2025. That is up 15.4% from -$79.85M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$2.32M (FY 2012) to -$67.53M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $206.84M | $10.04M | $86.11M | $56.78M | $65.10M | $213.49M |